Dihydrolycorine is a derivative of Lycorine, the main phenanthridine Amaryllidaceae alkaloid which exhibits significant antitumor activity in cancer cells that display resistance to proapoptotic stimuli.
Dihydrolycorine is a derivative of the alkaloid lycorine that has antihypertensive and neuroprotective activities. It inhibits methoxamine-induced contraction of isolated rabbit aortic rings and rat anococcygeus muscle with pA2 values of 5.93 and 6.35, respectively. Dihydrolycorine reduces mean arterial pressure (MAP) in anesthetized and conscious normotensive rats when administered at a dose of 80 mg/kg. It also reduces electrically or phenylephrine-induced hypertension in pithed rats. Dihydrolycorine reduces infarct size, cerebral edema, and myeloperoxidase activity in a rat model of focal cerebral ischemia-reperfusion injury when administered following reperfusion.
Colorless columnar crystals, soluble in organic solvents such as methanol, ethanol, and DMSO, derived from Lycoris radiata bulbs.
Dihydrolycorine is a derivative of Lycorine (L487550), the main phenanthridine Amaryllidaceae alkaloid which exhibits significant antitumor activity in cancer cells that display resistance to proapoptotic stimuli.
Dihydrolycorine inhibits methoxamine-induced contraction of isolated rabbit aortic rings and rat anococcygeus muscle with pA2 values of 5.93 and 6.35, respectively[2].
[1] B Y CHEN. [Hypotensive effect of dihydrolycorine].[J]. Zhongguo yao li xue bao = Acta pharmacologica Sinica, 1993, 14 1: 45-49.
[2] HONG-YAN CHEN. [Protective effect of hyperin on focal cerebral ischemia reperfusion injury in rats].[J]. Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine, 2006, 4 5: 526-529. DOI:
10.3736/jcim20060518
